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bstract
urpose: To retrospectively evaluate whether baseline nodule density or changes in density or nodule features could be used to discriminate
etween benign and malignant solid indeterminate nodules.
aterials and methods: Solid indeterminate nodules between 50 and 500 mm3 (4.6–9.8 mm) were assessed at 3 and 12 months after baseline
ung cancer screening (NELSON study). Nodules were classified based on morphology (spherical or non-spherical), shape (round, polygonal or
rregular) and margin (smooth, lobulated, spiculated or irregular). The mean CT density of the nodule was automatically generated in Hounsfield
nits (HU) by the Lungcare© software.
esults: From April 2004 to July 2006, 7310 participants underwent baseline screening. In 312 participants 372 solid purely intra-parenchymal
odules were found. Of them, 16 (4%) were malignant. Benign nodules were 82.8 mm3 (5.4 mm) and malignant nodules 274.5 mm3 (8.1 mm)
p = 0.000). Baseline CT density for benign nodules was 42.7 HU and for malignant nodules −2.2 HU (p = ns). The median change in density for
enign nodules was −0.1 HU and for malignant nodules 12.8 HU (p < 0.05). Compared to benign nodules, malignant nodules were more often
on-spherical, irregular, lobulated or spiculated at baseline, 3-month and 1-year follow-up (p < 0.0001). In the majority of the benign and malignant
odules there was no change in morphology, shape and margin during 1 year of follow-up (p = ns).
onclusion: Baseline nodule density and changes in nodule features cannot be used to discriminate between benign and malignant solid
ndeterminate pulmonary nodules, but an increase in density is suggestive for malignancy and requires a shorter follow-up or a biopsy.
2008 Elsevier Ireland Ltd. All rights reserved.eywords: CT screening; Lung cancer; Attenuation; Indeterminate nodules∗ Corresponding author. Tel.: +86 2164369181; fax: +86 2164701361.
E-mail address: dongming1996@hotmail.com (D.M. Xu).
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oi:10.1016/j.ejrad.2008.02.022. IntroductionLung cancer is today the most frequent cause of cancer deaths
n the world [1]. It currently accounts for approximately 5% of
ll deaths in most developed countries and, as such, constitutes a
ajor public health problem [2]. The overall 5-year survival rate
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f lung cancer patients is only 14%, and remained at this level
or the past two decades. However, when lung cancer is found
t the early stage I or II, 5-year survival rates can be as high
s 60–70% [3]. The rapid development of Multi-Detector Com-
uted Tomography (MDCT) technology and Computer-Aided
iagnosis (CAD) systems has led to a revival of interest in lung
ancer screening. The concept of CT screening for lung cancer
s based on the hypothesis that with an increase in the propor-
ion of tumors detected at an early stage [4] and a corresponding
eduction of advanced stage disease, a reduction of lung cancer
ortality can be achieved. From lung cancer screening trials we
now that 55–85% of screening detected lung cancer cases are
t an early stage [5], but whether this will result in a stage shift
r a lung cancer mortality reduction is yet unknown [6], and can
nly be answered by randomised lung cancer screening trials.
Aside from the primary research question whether lung can-
er screening is effective or not, the optimal management of
T detected pulmonary nodules is also of major clinical rel-
vance. CT screening reveals small sub-centimetre nodules
n 60–90% of screening participants and the differentiation
etween benign and malignant nodules is complicated [7,8].
anagement of these nodules should focus on rapid identifica-
ion of malignant nodules to make curative treatment possible,
hile avoiding needle biopsies and surgical resections for benign
esions. It is well known that size is an important discrimi-
ator: nodules less than 3 mm in diameter only have a 0.2%
hance of being malignant, but for nodules between 4 and
mm it is already 0.9%, between 8 and 20 mm 18% and above
0 mm 50% [9]. Based on these data, the Fleischner Society [9]
as issued recommendations for periodic follow-up scanning
epending on the initial size of the nodule and patient char-
cteristics. In addition to size, nodule consistency (i.e. solid,
artial-solid, non-solid) and nodule growth are also predictors
or malignancy [9–11]. However, benign lesions may grow as
ell [11], and two-dimensional measurements have proven to
e unreliable in detecting growth in small non-calcified nodules
12]. Therefore, additional nodule characteristics are needed to
ome to a better identification of malignant pulmonary nod-
les.
It has been demonstrated for non-solid and partial-solid nod-
les, usually representing bronchiolo-alveolar cell carcinomas
BAC) and adenocarcinomas, that during the malignant trans-
ormation nodule attenuation increase due to invasive growth,
lveolar collapse and fibrotic reactions [13]. It could be hypothe-
ised that during the evolution of small solid pulmonary nodules
similar change in nodule density might take place, which could
elp in the discrimination between benign and malignant solid
ulmonary nodules. Unknown is also if in the natural history of
alignant solid pulmonary nodules the external features might
hange from spherical, round and smooth to non-spherical, irreg-
lar, lobulated and spiculated.
Purpose of our study was to evaluate whether nodule density
r changes in nodule density, morphology, shape and margin
uring 1 year of follow-up in indeterminate solid pulmonary
odules between 50 and 500 mm3 detected at baseline screen-
ng for lung cancer could be used as parameters to discriminate
etween benign and malignant nodules.
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. Materials and methods
.1. Study participants
The subjects of this study were participants of the
utch–Belgian randomised trial for lung cancer screening
NELSON) who underwent baseline screening for lung can-
er by low-dose MDCT. Participants were between 50 and
5 years of age and were recruited via population registries
hrough mail. They had to be current or former smokers with
smoking history of >15 cigarettes/day for >25 years or >10
igarettes/day for >30 years. People who had had a pneu-
onectomy or with a history of breast cancer, melanoma or
ypernephroma were excluded. People with a history of other
ypes of cancer were only eligible if curatively treated at least
years ago without signs of recurrence at the time of inclu-
ion. The NELSON study was approved by the Medical Ethical
ommittees of all institutions and all subjects provided their
ritten informed consent. For the present study all partic-
pants with indeterminate solid nodules, defined as nodules
ith a volume between 50 and 500 mm3 (corresponding to
.6–9.8 mm in diameter), detected at baseline screening were
elected. These subjects underwent a follow-up CT scan at 3
nd 12 months to evaluate whether nodule density or changes
n nodule density, morphology, shape and margin could be used
s parameters to discriminate between benign and malignant
odules.
.2. Data acquisition
At all four screening sites 16-detector MDCT scanners
ere used (Mx8000 IDT or Brilliance 16P, Philips Medical
ystems, Cleveland, OH, USA, or Sensation-16, Siemens Med-
cal Solutions, Forchheim, Germany). Scanning of the entire
hest was performed in caudo-cranial direction. Scan data
ere obtained in spiral mode, with 16 mm × 0.75 mm collima-
ion and 1.5 pitch. No contrast was used. Low-dose settings
ere applied depending on body weight (<50 kg, 50–80 kg
nd >80 kg), the kVp settings were 80–90, 120 and 140 kVp,
espectively, to achieve a Computed Tomography Dose Index
olume (CTDIvol) of approximately 0.8 mGy, 1.6 mGy and
.2 mGy, respectively. The mAs settings were adjusted accord-
ngly, depending on the machine used. To minimise breathing
rtefacts, scans were performed at suspended maximal inspi-
ation after appropriate instruction of the subjects. Data were
econstructed at 1.0 mm slice thickness, with 0.7 mm recon-
truction increment. Repeat scans were performed with the same
echnical parameters as used for the baseline scans in low-dose
etting.
.3. Image analysis
All CT images were read twice independently. First read-
ngs were done by a radiologist with an experience in reading
horacic CT scans varying from 1 year to more than 20
ears. Second readings were done by radiologists with 6
ears of experience. In case of a discrepancy between the
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(Table 2). The median volume of all the nodules at baseline
was 84.9 mm3 (range 50.3–498.0 mm3, corresponding diameter
5.5 mm). For benign nodules the median volume was 82.8 mm3
(range 50.3–491.0 mm3, corresponding diameter 5.4 mm) and
Table 1
Distribution of morphology, shape and margin in 372 solid indeterminate pul-
monary nodules detected at baseline, 3-month and 1-year follow-up scan
Indeterminate nodules
Baseline (%) 3-month FU (%) 1-year FU (%)
Morphology
Spherical 338 (91) 336 (90) 329 (91)
Non-spherical 34 (9) 36 (10) 33 (9)
Shape
Polygonal 42 (11) 41 (11) 42 (12)
Round 285 (77) 285 (77) 279 (77)
Irregular 45 (12) 46 (12) 41 (11)
Margin
Smooth 260 (70) 274 (74) 251 (69)
Lobulated 74 (20) 57 (15) 76 (21)
Spiculated 38 (10) 41 (11) 35 (10)94 D.M. Xu et al. / European Jour
rst and second reader, a third radiologist with more than
5 years of experience in thoracic CT made the final deci-
ion. The Syngo Lungcare© (Leonardo© workstation, Somaris/5
B 10A, Siemens Medical Solutions, Erlangen, Germany)
oftware package designed to aid radiologists in diagnosing
ulmonary nodules was used in addition to visual read-
ngs. Baseline and follow-up images were reviewed and
isplayed simultaneously on one workstation. All images
ere interpreted both at lung window and mediastinal set-
ings.
.4. Nodule features
Non-calcified solid nodules detected at baseline screening
ere classified into four different categories based on size and
enign characteristics [14]. Nodules with volumes between 50
nd 500 mm3 (corresponding to 4.6–9.8 mm in diameter) were
efined as indeterminate nodules. These nodules were further
lassified based on morphology (spherical or non-spherical),
hape (round/oval, polygonal or irregular) [15] and margin
smooth, lobulated, spiculated or irregular) [16]. The mean CT
ensity of all voxels within the outer margin of the nodule was
utomatically generated in Hounsfield units (HU) by Lungcare©
oftware, instead of specifying a region of interest (ROI) for
ensity measurement. In case of inappropriate segmentation,
he radiologist was able to enter manual measurements as well,
hich then overruled the automatically generated density and
olume as described earlier [14]. A nodule was defined as
pherical if the maximal diameter was less than twice the min-
mal diameter of the nodule, otherwise non-spherical. A nodule
as polygonal when the entire lesion surface was surrounded
y concave margins [17]. Spiculation was defined as the pres-
nce of strands extending from the nodule margin into the lung
arenchyma without reaching the pleural surface [18]. Lobula-
ion was defined as an abrupt bulging of the lesion contour [19].
ecause all indeterminate nodules received a follow-up scan at
months and 1 year according to the NELSON trial protocol
14], three time points were available for analysis in all nod-
les except for the nodules that appeared to be malignant at 3
onths.
.5. Study endpoints
A participant with a nodule showing significant growth at 3-
onth or 1-year follow-up was referred to a pulmonologist for
ork-up and final pathological diagnosis [14]. Nodules were
lassified as benign or malignant based on histological exam-
nation of a trans-thoracic needle biopsy or examination of
urgical specimens. Nodules were also classified as benign if
he Volume Doubling Time (VDT) was >600 days or if the
olume decreased or the nodule resolved at 1-year follow-
p..6. Statistical analysis
The Mann–Whitney U-test was used for comparisons of vol-
me, density and the volume, density change over time between
T
F
nRadiology 70 (2009) 492–498
enign and malignant nodules. For benign and malignant
odules with 1-year follow-up scan, the change in atten-
ation was defined as the density at year one minus the
ensity at the 3-month repeat scan. For malignant nodules
iagnosed at 3-month follow-up, the attenuation change (CT
ensity change) was defined as the density at 3 months minus
he density at baseline scan. Changes in morphology, shape
nd margin between baseline, 3-month and 1-year follow-up
ere compared by χ2-test, both for benign and malignant
odules. P-values <0.05 were considered statistically signifi-
ant. All statistical analyses were performed by SPSS version
4.0.
. Results
From April 2004 to July 2006, 7310 participants under-
ent baseline screening. The mean age of the participants
as 63 years (±5 years), 95% were males, 5% females. In
12 participants 372 solid purely intra-parenchymal nodules
ith a volume between 50 and 500 mm3 were found. The
istribution in morphology, shape and margin at baseline, 3-
onth and 1-year follow-up is presented in Table 1. Of the
72 nodules, 16 (4%) turned out to be malignant and 356
96%) were benign. Ten cases of lung cancer (nos. 1–10)
ere diagnosed at 3-month and 6 cancer cases (nos. 11–16)
t 1-year follow-up. These 6 malignant nodules did not show
rowth at 3-month follow-up. Among these 16 lung cancer
ases, there were 8 adenocarcinomas, 5 squamous cell carcino-
as, 2 large cell carcinomas and 1 neuroendocrine carcinomaotal 372 372 362a
U, follow-up.
a At 1-year FU, there were 362 nodules instead of 372 nodules, since 10
odules were diagnosed as lung cancer at 3-month FU.
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Table 2
CT density, morphology, shape and margin changes over time in 16 malignant solid indeterminate nodules
No. Scan time Volume (mm3) (diameter, mm) Density (HU) Morphology Shape Margin Histology
1 Baseline 446.6 (9.5) 67.2 Spherical Round Lobulated Squamous cell carcinoma
3 months 1102.0 (12.8) 37.7 Spherical Round Spiculated
2 Baseline 249.8 (7.8) 57.5 Spherical Irregular Spiculated Squamous cell carcinoma
3 months 362.2 (8.8) 28.7 Spherical Irregular Spiculated
3 Baseline 262.9 (7.9) −2.6 Non-spherical Irregular Spiculated Adenocarcinoma
3 months 1132 (12.9) −14.6 Non-spherical Irregular Spiculated
4 Baseline 458.7 (9.6) 48.4 Spherical Round Lobulated Adenocarcinoma
3 months 601.4 (10.4) 46.9 Spherical Round Lobulated
5 Baseline 124.8 (6.2) 75.0 Spherical Round Lobulated Adenocarcinoma
3 months 337.6 (8.6) 73.8 Spherical Round Lobulated
6 Baseline 64.4 (5.0) 21.4 Spherical Round Lobulated Squamous cell carcinoma
3 months 87.6 (5.5) 34.6 Spherical Round Lobulated
7 Baseline 279.4 (8.1) −20.1 Non-spherical Irregular Spiculated Adenocarcinoma
3 months 460.5 (9.6) −6.8 Non-spherical Irregular Spiculated
8 Baseline 308.8 (8.4) −41.8 Non-spherical Irregular Spiculated Neuroendocrine
3 months 774.3 (11.4) −13.3 Non-spherical Irregular Spiculated Carcinoma
9 Baseline 302.5 (8.3) −57.6 Spherical Round Lobulated Squamous cell carcinoma
3 months 575.6 (10.3) −14.6 Spherical Round Lobulated
10 Baseline 121.8 (6.1) −1.8 Non-spherical Irregular Lobulated Large cell
3 months 1223 (13.3) 43.3 Non-spherical Irregular Lobulated Carcinoma
11 Baseline 346.3 (8.7) −128 Non-spherical Irregular Spiculated Adenocarcinoma
3 months 160.7 (6.7) −77.7 Non-spherical Irregular Spiculated
One year 780.3 (11.4) −38.1 Non-spherical Irregular Spiculated
12 Baseline 498.0 (9.8) −13.0 Non-spherical Irregular Lobulated Large cell
3 months 450.2 (9.5) −13.0 Non-spherical Irregular Lobulated Carcinoma
1 year 698.2 (11.0) 16.4 Non-spherical Irregular Lobulated
13 Baseline 242.2 (7.7) −57.3 Spherical Irregular Spiculated Adenocarcinoma
3 months 282.3 (8.1) −57.1 Spherical Irregular Spiculated
1 year 496.5 (9.8) −32.9 Spherical Irregular Spiculated
14 Baseline 269.5 (8.0) 24.9 Non-spherical Irregular Spiculated Adenocarcinoma
3 months 252.0 (7.8) 10.8 Non-spherical Irregular Spiculated
1 year 483.5 (9.7) 23.1 Non-spherical Irregular Spiculated
15 Baseline 382.7 (9.0) −14.8 Non-spherical Irregular Lobulated Squamous cell carcinoma
3 months 281.0 (8.1) −22.5 Non-spherical Irregular Lobulated
1 year 1765 (15.0) −23.5 Non-spherical Irregular Lobulated
16 Baseline 227.7 (7.6) 56.7 Non-spherical Irregular Spiculated Adenocarcinoma
3 months 275.4 (8.1) 29.3 Non-spherical Irregular Spiculated
1 year 448.0 (9.5) 37.8 Non-spherical Irregular Spiculated
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−or malignant nodules 274.5 mm3 (range 64.4–498.0 mm3, cor-
esponding diameter 8.1 mm) (p = 0.000). The median volume
hange over time for benign nodules was 1.7 mm3 (range
2220.4 to 950.5 mm3, corresponding diameter 1.5 mm) and for
alignant nodules 231.5 mm3 (range 23.2–1483.5 mm3, corre-
ponding diameter 7.6 mm) (p = 0.000).
Compared to benign nodules, malignant nodules were more
ften non-spherical, irregular, lobulated or spiculated at base-
ine, 3-month and 1-year follow-up (p < 0.0001). In 356 benign
odules, 99% had no change in morphology and shape, and
n 86% of them no change in margin during 1 year of follow-
p. Of the 16 malignant nodules, 15 nodules had no margin
−
f
a
(hange, and all these malignant nodules had no change in mor-
hology or shape at 3 months or 1 year of follow-up. There
as no significant difference of morphology, shape and margin
hange between benign and malignant nodules during follow-up
can (p = ns) (Table 3).
Baseline median CT density for all nodules was 41.6 HU
range −195.0 to 192.1 HU), for benign nodules 42.7 HU (range
195.1 to 192.1 HU) and for malignant nodules −2.2 HU (range
127.5 to 75.0 HU) (p = ns). The median change in density
or benign nodules was −0.1 HU (range −93.1 to 175.2 HU)
nd 12.8 HU (range −29.5 to 45.1 HU) for malignant nodules
p < 0.05) (Fig. 1).
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Table 3
Distribution of morphology, shape and margin change in 372 solid indeterminate pulmonary nodules at 3-month or 1-year follow-up scan between benign and
malignant nodules
Morphology Shape Margin
No change Change No change Change No change Change
Benign (356) 353 (99) 3 (1) 351 (99) 5 (1) 305 (86) 51 (14)
Malignant (16) 16 (100) 0 (0)* 16 (100) 0 (0)* 15 (94) 1 (6)*
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* p > 0.05 (χ2-test).
. Discussion
The management algorithm of pulmonary nodules found at
aseline scans is based on size and the consistency of the nodules
solid, partial-solid or non-solid). According to our NELSON
rotocol, a non-calcified nodule with a volume between 50 and
00 mm3 was classified as indeterminate because of its interme-
iate cancer risk. They required an additional repeat scan 3–4
onths later to assess growth and to get additional information
egarding the nature of these nodules [14]. In approximately 20%
f participants of the NELSON trial, at least one indeterminate
odule was detected, making this type of nodule rather common.
ecause the clinical importance of providing an optimal nodule
anagement algorithm for indeterminate pulmonary nodules is
igh, we decided to focus on this type of nodule to investigate
f changes in nodule attenuation, shape, morphology or margin
ere associated with malignancy.
First of all we observed in our series that the malignant
odules tended to have a lower mean density than the benign
odules, without reaching statistical significance. This might
e explained by the inclusion of air, an air bronchogram or
egressive changes such as necrosis or hemorrhage within the
umor. These findings are consistent with the results of studies
erformed in usually larger SPNs [20–23]. Therefore, nod-
le density cannot be used in clinical practice to discriminate
ig. 1. Attenuation changes (Hounsfield units) in 356 benign and 16 malignant
olid indeterminate pulmonary nodules at 3-month or 1-year follow-up.
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etween malignant and benign nodules because of the wide over-
ap observed in our series as well as by others in larger solitary
ulmonary nodules [20,21,24].
The second observation was that malignant solid nodules
howed a significant increase in density at 3-month or 1-year
ollow-up. This observation could be used to recommend a
horter follow-up (i.e. after 6 or 9 months) or to biopsy this
ype of nodules because of an increased cancer risk. Although
o serial pathological specimens are available in this study
nd no pathological–radiological correlate can be provided, the
bserved increase in density might be reflecting the evolution
f small adenocarcinomas described by Noguchi et al. [25]. In
he transition from atypical adenomatous hyperplasia (AAH)
o bronchiolo-alveolar cell carcinoma (BAC), adenocarcinoma
ith BAC features and invasive adenocarcinoma, there was a
ecrease in alveolar and lepidic growth pattern and an increase
n invasive growth and fibrosis formation. On the other hand,
ccording to the results of the present study, benign lesions did
ot show this change in nodule density over time, but instead
howed large individual increases or decreases. Since there was
o pathological material available from these benign nodules
t can only be speculated what the underlying cause might
e, including the spontaneous resolution of infectious lesions
r local mucus impaction. Lymph nodes are less likely to be
nvolved since the indeterminate nodules selected were situ-
ted within the lung parenchyma, while lymph nodes usually
re located in the close vicinity of the broncho-vascular tree, the
ubpleural area or area attached to fissures [26,27].
The third observation in our series is that malignant indeter-
inate solid nodules are already from the beginning larger and
ore often non-spherical, irregular, lobulated or spiculated than
enign lesions, suggesting that the malignant features are not
cquired in the course of their natural history.
So far, only the investigators of the Mayo Clinic lung cancer
T screening trial described in detail the changes in attenua-
ion and margin in 48 lung cancer cases in which more than one
T examination was available [28]. Nodule attenuation was, in
ontrast to our study, not measured but the nodules were only
isually classified as solid, partial-solid and non-solid. In 44%
21/48) of the cases the attenuation changed: in 57% it increased
from non-solid to partial-solid or solid), in 24% it decreased
nd in the remaining 19% it was variable. In 42% (20/48) the
argin of the nodule changed: in 80% it became more irregu-
ar or spiculated, in 15% smoother and the margin was variable
n 5%. As these changes in attenuation and margin were lim-
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[D.M. Xu et al. / European Jour
ted to malignant nodules only in their study, no conclusion
an be drawn with regard to the value of density and margin
hanges in the discrimination between benign and malignant
odules.
Although our study represents, to our knowledge one of the
argest prospective series of CT screening-detected solid and
urely intra-parenchymal indeterminate nodules in which ret-
ospectively the changes in attenuation, morphology, shape and
argin have been evaluated, our study is limited by the rela-
ively small numbers of lung cancer cases. Another limitation of
ur study is that in the majority of the benign nodules no histo-
ogical or cytological diagnosis of the lesion could be obtained
espite intensive work-up by the pulmonologist including bron-
hoscopy, brush and washing. Usually, the nodule could not
e reached by trans-thoracic needle biopsy or video-assisted
horacoscopy because of their location or small size. If no patho-
ogical confirmation was obtained a nodule was only classified
s benign if the VDT was >600 days or if the volume decreased
t 1 year of follow-up. As our study had only a 1-year follow-up
eriod, some of these nodules may turn out to be cancer in a
ater stage although this probability is rather low [29]. The third
imitation is that we do not have information on the repeata-
ility and reproducibility of the nodule density measurements.
herefore, the observed nodule density changes could also be a
esult of the variability in nodule density measurements. How-
ver, as this potential variability applies both for benign and
alignant nodules, it will not change the conclusions of our
tudy.
In conclusion, baseline nodule density and changes in nod-
le features cannot be used to discriminate between benign
nd malignant solid indeterminate pulmonary nodules, but an
ncrease in density is suggestive for malignancy and requires a
horter follow-up or a biopsy.
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